Paris – (Business Wire) – Regulatory News:
CARMAT (FR0010907956, ALCAR, Eligible PEA-PME) (Paris: ALCAR) is the world’s most advanced artificial heart project aimed at providing alternative therapies for patients suffering from end-stage biventricular heart failure. Designers and developers. Our Shareholders’Meeting and our Joint General Meeting will be held on Wednesday, May 11, 2022 at 10 am at the Business Center Edouard VII in 75009 Paris Edouard VII Square in Paris. Shareholders and the entire financial community.
Under current health conditions, we encourage shareholders to support remote or proxy voting. For shareholders wishing to attend the General Meeting of Shareholders, please note that acceptance of shareholders is subject to barrier gestures, especially wearing a mask during the General Meeting of Shareholders.
If shareholders do not attend this meeting directly, they may exercise their voting rights remotely before the general meeting.
By sending the adult guardianship system to the company
By exercising voting rights by mail
Use the voting form available at www.carmatsa.com by following the steps given in the advance notice published at BALO on April 6, 2022.
All documents related to this General Assembly are available upon request from the company. Alternatively, you can find it in the Investors / Documents / General Assembly on the company website.
Given the uncertainties associated with the Covid-19 epidemic, we may be guided to change the procedures for holding, attending, and voting for the General Assembly in accordance with applicable legal and regulatory provisions. Therefore, shareholders are encouraged to regularly refer to the section dedicated to the General Meeting of Shareholders on our website.
CARMAT is a French Medtech company that designs, manufactures and sells Aeson® artificial hearts. The company aims to make Aeson® the first alternative to heart transplantation and provide a therapeutic solution for patients suffering from advanced biventricular heart failure who are notorious for the lack of available human grafts. I am. Aeson®, the world’s first blood-compatible, pulsatile, and self-regulating physiological artificial heart, can save thousands of patients awaiting a heart transplant each year. The device provides the patient’s quality of life and mobility thanks to an ergonomic and portable external power system that is permanently connected to the embedded prosthesis. Aeson® is marketed as a “bridge to transplant” label in the European Union and other countries that recognize the CE mark. Aeson® is currently being evaluated in clinical feasibility studies in the United States. Founded in 2008, CARMAT is located in the Paris region, headquartered in Belize Biracbree and production in Bois d’Arci. The company relies on the talent of an interdisciplinary team of over 200 highly specialized people. Listed on the Euronext Growth Market in Paris (ticker: ALCAR / ISIN: FR0010907956).
For more information, please visit www.carmatsa.com and follow us on LinkedIn.
wording: Car mat
This press release and the information contained therein do not constitute a sale or subscription offer, or a purchase or subscription order solicitation for CARMAT shares in any country. This press release may contain forward-looking statements regarding the company’s objectives and perspectives. These forward-looking statements are based on the company’s management’s current estimates and expectations, the ability to execute the company’s strategy, the rate of development of CARMAT production and sales, the pace, ongoing or planned clinical practice. Test results, technology development and competitive environment, regulatory changes, industrial risks, and all risks associated with managing the company’s growth. Our objectives set forth in this press release may not be achieved due to these or other risk and uncertainty factors.
Our significant and specific risk is the risk described in the Universal Registration Document submitted to Autorité des Marchés Financiers (AMF) under number D.21-0076. However, the attention of readers and investors is drawn to the fact that there may or may be other risks that are unknown or not considered significant and specific.
Aeson® is an active implantable medical device marketed with the CE mark recognized in the European Union and other countries. Aeson® Total Artificial Heart is intended to replace the original ventricle of the heart, is the maximum medical treatment and left ventricular assist device (LVAD), and is eligible for a heart transplant within 180 days after transplantation. .. Transplant decisions and surgical procedures should be made by medical professionals trained by the manufacturer. Carefully read the documentation (clinical manual, patient manual, alarm booklet) to find out the characteristics of Aeson® and the information needed for Aeson® patient selection and proper use (contraindications, precautions, secondary effects). You need to understand. In the United States, Aeson® is currently only available in clinical feasibility studies approved by the Food and Drug Administration (FDA).
Management and Finance Director Tel. : 01 39 45 64 50
like that. : 06 64 18 99 59
Financial communication and public relations for investors
like that. : 01 44 71 94 92 92